NASDAQ:QURE

uniQure Stock Forecast, Price & News

$29.16

-0.58 (-1.95 %)

(As of 07/29/2021 12:00 AM ET)

Add

Compare

Today's Range

$28.84

▼

$30.24

50-Day Range

$26.01

▼

$37.17

52-Week Range

$25.80

▼

$52.19

Volume413,459 shs

Average Volume434,016 shs

Market Capitalization$1.34 billion

P/E RatioN/A

Dividend YieldN/A

Beta1.22

30 days | 90 days | 365 days | Advanced Chart

Receive QURE News and Ratings via Email

Sign-up to receive the latest news and ratings for uniQure and its competitors with MarketBeat's FREE daily newsletter.

About uniQure

uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-180 for the treatment of hemophilia A; AMT-190, an IV-administered adeno-associated virus (AAV) 5-based gene therapy for the treatment of Fabry disease; and AMT-150, a one-time, intrathecally-administered, AAV gene therapy for treating spinocerebellar ataxia type 3. The company has collaboration and license agreements with Bristol Myers-Squibb Company; Gen-X; and Synpromics Limited. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

James' unique style took him on Hall of Fame journey - Fox News
July 29, 2021 | foxnews.com

Robinhood's unique IPO is a clever defense against competitors - Yahoo Finance
July 29, 2021 | finance.yahoo.com

M1's new credit card comes with a unique twist - Chicago Business Journal
July 28, 2021 | bizjournals.com

uniQure Announces Second Quarter 2021 Financial Results and Highlights Recent Company Progress - Yahoo Finance
July 27, 2021 | finance.yahoo.com

uniQure's (QURE) Buy Rating Reiterated at Chardan Capital
July 27, 2021 | americanbankingnews.com

Carmichael used unique size to become Hall of Fame wideout - Fox News
July 27, 2021 | foxnews.com

Explainer: What we know about inter-Korean hotlines, unique symbol for testy ties - Reuters
July 27, 2021 | reuters.com

Raiders sign punter Corliss Waitman with unique backstory - Raiders Wire
July 26, 2021 | raiderswire.usatoday.com

UniQure (QURE) Q2 Earnings and Revenues Top Estimates - Yahoo Finance
July 26, 2021 | finance.yahoo.com

uniQure (NASDAQ:QURE) Shares Gap Up to $26.01
July 26, 2021 | americanbankingnews.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:QURE
Previous Symbol
CUSIPN/A
CIK1590560
Webwww.uniqure.com
Phone31-20-240-6000
Employees332
Year FoundedN/A

Sales & Book Value

Annual Sales$37.51 million
Price / Sales35.82
Cash FlowN/A
Price / Cash FlowN/A
Book Value$5.48 per share
Price / Book5.32

Profitability

EPS (Most Recent Fiscal Year)($2.81)
Net Income$-125,020,000.00
Net Margins-366.00%
Return on Equity-57.38%
Return on Assets-38.49%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares46,073,000
Market Cap$1.34 billion
Next Earnings Date10/26/2021 (Estimated)
OptionableOptionable

MarketRank^™

Overall MarketRank^™

1.97 out of 5 stars

Medical Sector

304th out of 2,214 stocks

Pharmaceutical Preparations Industry

152nd out of 869 stocks

4.5 Analyst's Opinion

Consensus Rating
uniQure has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 12 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $60.88, uniQure has a forecasted upside of 108.8% from its current price of $29.16.
Amount of Analyst Coverage
uniQure has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.7 Community Rank

Outperform Votes
uniQure has received 608 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
uniQure has received 222 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
uniQure has received 73.25% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about uniQure and other stocks. Vote “Outperform” if you believe QURE will outperform the S&P 500 over the long term. Vote “Underperform” if you believe QURE will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
uniQure does not currently pay a dividend.
Dividend Growth
uniQure does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, uniQure insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $785,722.00 in company stock.
Percentage Held by Insiders
Only 2.68% of the stock of uniQure is held by insiders.
Percentage Held by Institutions
77.82% of the stock of uniQure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Earnings Growth
Earnings for uniQure are expected to decrease in the coming year, from $1.94 to ($1.03) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of uniQure is -9.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of uniQure is -9.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
uniQure has a P/B Ratio of 5.32. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

uniQure (NASDAQ:QURE) Frequently Asked Questions

Is uniQure a buy right now?

14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for uniQure in the last twelve months. There are currently 1 hold rating, 12 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" uniQure stock.
View analyst ratings for uniQure or view top-rated stocks.

What stocks does MarketBeat like better than uniQure?

Wall Street analysts have given uniQure a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but uniQure wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is uniQure's next earnings date?

uniQure is scheduled to release its next quarterly earnings announcement on Tuesday, October 26th 2021.
View our earnings forecast for uniQure.

How were uniQure's earnings last quarter?

uniQure (NASDAQ:QURE) issued its earnings results on Sunday, July, 25th. The biotechnology company reported $8.51 EPS for the quarter, topping the Zacks' consensus estimate of $2.97 by $5.54. uniQure had a negative trailing twelve-month return on equity of 57.38% and a negative net margin of 366.00%.
View uniQure's earnings history.

How has uniQure's stock price been impacted by COVID-19 (Coronavirus)?

uniQure's stock was trading at $47.54 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, QURE stock has decreased by 38.7% and is now trading at $29.16.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for QURE?

14 equities research analysts have issued 12-month target prices for uniQure's stock. Their forecasts range from $27.46 to $95.00. On average, they anticipate uniQure's stock price to reach $60.88 in the next twelve months. This suggests a possible upside of 108.8% from the stock's current price.
View analysts' price targets for uniQure or view top-rated stocks among Wall Street analysts.

Who are uniQure's key executives?

uniQure's management team includes the following people:

Mr. Matthew Craig Kapusta, CEO, CFO & Exec. Director (Age 49, Pay $965.48k)
Mr. Christian Klemt, Chief Accounting Officer (Age 48, Pay $392.6k)
Dr. Alexander E. Kuta Ph.D., Exec. VP of Operations (Age 61, Pay $652.58k)
Dr. Ricardo Dolmetsch Ph.D., Pres of R&D (Age 52, Pay $626.15k)
Prof. Hugo Katus, Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany
Mr. Pierre Caloz, Chief Operating Officer
Mr. David Cerveny, Chief Legal Officer, Gen. Counsel & Sec. (Age 54)
Ms. Maria E. Cantor, Chief Communications Officer (Age 53)
Dr. Tamara Tugal Ph.D., MBA, Bus. Devel. Director
Mr. James Brady, Chief HR Officer

What is Matthew Kapusta's approval rating as uniQure's CEO?

8 employees have rated uniQure CEO Matthew Kapusta on Glassdoor.com. Matthew Kapusta has an approval rating of 74% among uniQure's employees.

Who are some of uniQure's key competitors?

Some companies that are related to uniQure include Apellis Pharmaceuticals (APLS), Arvinas (ARVN), Ionis Pharmaceuticals (IONS), TG Therapeutics (TGTX), Blueprint Medicines (BPMC), Schrödinger (SDGR), Reata Pharmaceuticals (RETA), Hypera (HYPMY), Allakos (ALLK), Cassava Sciences (SAVA), Alkermes (ALKS), Galapagos (GLPG), Arena Pharmaceuticals (ARNA), ACADIA Pharmaceuticals (ACAD) and Emergent BioSolutions (EBS).
View all of QURE's competitors.

What other stocks do shareholders of uniQure own?

Based on aggregate information from My MarketBeat watchlists, some companies that other uniQure investors own include Empire Resorts (NYNY), Micron Technology (MU), Gilead Sciences (GILD), Alibaba Group (BABA), AbbVie (ABBV), GW Pharmaceuticals (GWPH), NVIDIA (NVDA), Exelixis (EXEL), Square (SQ) and bluebird bio (BLUE).

What is uniQure's stock symbol?

uniQure trades on the NASDAQ under the ticker symbol "QURE."

How do I buy shares of uniQure?

Shares of QURE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is uniQure's stock price today?

One share of QURE stock can currently be purchased for approximately $29.16.

How much money does uniQure make?

uniQure has a market capitalization of $1.34 billion and generates $37.51 million in revenue each year. The biotechnology company earns $-125,020,000.00 in net income (profit) each year or ($2.81) on an earnings per share basis.

How many employees does uniQure have?

uniQure employs 332 workers across the globe.

What is uniQure's official website?

The official website for uniQure is www.uniqure.com.

Where are uniQure's headquarters?

uniQure is headquartered at PAASHEUVELWEG 25A, AMSTERDAM P7, 1105 BP.

How can I contact uniQure?

uniQure's mailing address is PAASHEUVELWEG 25A, AMSTERDAM P7, 1105 BP. The biotechnology company can be reached via phone at 31-20-240-6000 or via email at [email protected]

This page was last updated on 7/30/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here